Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Minglei Yang, Jian Zhao, Tielong Liu, Xinghai Yang, Haifeng Wei, Wei Xu & Jianru Xiao. (2018) Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis. Cancer Management and Research 10, pages 2635-2652.
Read now
Read now
Vu H Duong, Eric Padron, Alan F List & Rami S Komrokji. (2013) Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?. Expert Review of Hematology 6:5, pages 485-487.
Read now
Read now
Andrew Wei & Peter Tan. (2013) Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia. Leukemia & Lymphoma 54:4, pages 675-676.
Read now
Read now
Articles from other publishers (35)
Ali Bazarbachi, Myriam Labopin, Tobias Gedde-Dahl, Peter Remenyi, Edouard Forcade, Nicolaus Kröger, Gerard Socié, Charles Craddock, Jean Henri Bourhis, Jurjen Versluis, Ibrahim Yakoub-Agha, Urpu Salmenniemi, Jean El-Cheikh, Gesine Bug, Jordi Esteve, Arnon Nagler, Fabio Ciceri & Mohamad Mohty. (2023)
Improved Posttransplant Outcomes in Recent Years for AML Patients with
FLT3
-ITD and Wild-type
NPM1
: A Report from the EBMT Acute Leukemia Working Party
. Clinical Cancer Research 29:21, pages 4441-4448.
Crossref
Crossref
Prateek Pophali, Sudhamsh Reddy Desai & Aditi Shastri. (2023) Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents. Current Hematologic Malignancy Reports 18:3, pages 56-67.
Crossref
Crossref
Shristi Upadhyay Banskota, Nabin Khanal, Rosalyn I. Marar, Prajwal Dhakal & Vijaya Raj Bhatt. (2022) Precision Medicine in Myeloid Malignancies: Hype or Hope?. Current Hematologic Malignancy Reports 17:6, pages 217-227.
Crossref
Crossref
Elli D. Novatcheva, Yasmine Anouty, Ila Saunders, James K. Mangan & Aaron M. Goodman. (2022) FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 22:3, pages e161-e184.
Crossref
Crossref
Paul Lee, Rita Yim, Yammy Yung, Hiu-Tung Chu, Pui-Kwan Yip & Harinder Gill. (2021) Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome. International Journal of Molecular Sciences 22:19, pages 10232.
Crossref
Crossref
Rory M. Shallis & Amer M. Zeidan. (2021) Management of the Older Patient with Myelodysplastic Syndrome. Drugs & Aging 38:9, pages 751-767.
Crossref
Crossref
Simona Pagliuca, Carmelo Gurnari & Valeria Visconte. (2021) Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments. Cancers 13:4, pages 784.
Crossref
Crossref
Juan Eduardo Megías-Vericat, Octavio Ballesta-López, Eva Barragán, David Martínez-Cuadrón & Pau Montesinos. (2020) Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?. Blood Reviews 44, pages 100675.
Crossref
Crossref
Iman Abou Dalle, Ahmad Ghorab, Keyur Patel, Xuemei Wang, Hyunsoo Hwang, Jorge Cortes, Ghayas C. Issa, Fevzi Yalniz, Koji Sasaki, Dai Chihara, Allyson Price, Tapan Kadia, Naveen Pemmaraju, Naval Daver, Courtney DiNardo, Farhad Ravandi, Hagop M. Kantarjian & Gautam Borthakur. (2020) Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer Journal 10:5.
Crossref
Crossref
Bradley D. Hunter & Yi-Bin Chen. (2020) Current Approaches to Transplantation for FLT3-ITD AML. Current Hematologic Malignancy Reports 15:1, pages 1-8.
Crossref
Crossref
Seiji Kakiuchi, Kimikazu Yakushijin, Rina Sakai, Koji Kawaguchi, Ako Higashime, Keiji Kurata, Hiroya Ichikawa, Shigeki Nagao, Junpei Rikitake, Naomi Kiyota, Hiroshi Matsuoka & Hironobu Minami. (2018) Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia. Journal of Oncology Pharmacy Practice 25:8, pages 2010-2015.
Crossref
Crossref
Sonja Pavlović & Natasa Tosic. 2019. Personalized Medicine in Healthcare Systems. Personalized Medicine in Healthcare Systems
341
374
.
Maro Ohanian, Guillermo Garcia-Manero, Mark Levis, Elias Jabbour, Naval Daver, Gautam Borthakur, Tapan Kadia, Sherry Pierce, Jan Burger, Mary Ann Richie, Keyur Patel, Michael Andreeff, Zeev Estrov, Jorge Cortes, Hagop Kantarjian & Farhad Ravandi. (2018)
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated
FLT3
-ITD Mutated Acute Myeloid Leukemia
. American Journal of Hematology 93:9, pages 1136-1141.
Crossref
Crossref
Caner Saygin & Hetty E. Carraway. (2017) Emerging therapies for acute myeloid leukemia. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
Seah H. Lim, Patrycja M. Dubielecka & Vikram M. Raghunathan. (2017) Molecular targeting in acute myeloid leukemia. Journal of Translational Medicine 15:1.
Crossref
Crossref
Catrin Roolf, Nikolaj Dybowski, Anett Sekora, Stefan Mueller, Gudrun Knuebel, Andreas Tebbe, Hugo Murua Escobar, Klaus Godl, Christian Junghanss & Christoph Schaab. (2017) Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells. Molecular & Cellular Proteomics 16:7, pages 1365-1376.
Crossref
Crossref
Prithviraj Bose, Pankit Vachhani & Jorge E. Cortes. (2017) Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Current Treatment Options in Oncology 18:3.
Crossref
Crossref
James Mattina, Benjamin Carlisle, Yasmina Hachem, Dean Fergusson & Jonathan Kimmelman. (2017) Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLOS Biology 15:2, pages e2000487.
Crossref
Crossref
Jing Chen, Jiawei Guo, Zhi Chen, Jieqiong Wang, Mingyao Liu & Xiufeng Pang. (2016) Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer. Scientific Reports 6:1.
Crossref
Crossref
Catherine C. Coombs, Martin S. Tallman & Ross L. Levine. (2015) Molecular therapy for acute myeloid leukaemia. Nature Reviews Clinical Oncology 13:5, pages 305-318.
Crossref
Crossref
Christoph Röllig, Hubert Serve, Andreas Hüttmann, Richard Noppeney, Carsten Müller-Tidow, Utz Krug, Claudia D Baldus, Christian H Brandts, Volker Kunzmann, Hermann Einsele, Alwin Krämer, Kerstin Schäfer-Eckart, Andreas Neubauer, Andreas Burchert, Aristoteles Giagounidis, Stefan W Krause, Andreas Mackensen, Walter Aulitzky, Regina Herbst, Mathias Hänel, Alexander Kiani, Norbert Frickhofen, Johannes Kullmer, Ulrich Kaiser, Hartmut Link, Thomas Geer, Albert Reichle, Christian Junghanß, Roland Repp, Frank Heits, Heinz Dürk, Jana Hase, Ina-Maria Klut, Thomas Illmer, Martin Bornhäuser, Markus Schaich, Stefani Parmentier, Martin Görner, Christian Thiede, Malte von Bonin, Johannes Schetelig, Michael Kramer, Wolfgang E Berdel & Gerhard Ehninger. (2015) Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. The Lancet Oncology 16:16, pages 1691-1699.
Crossref
Crossref
David Sanford & Farhad Ravandi. (2015) Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions. Drugs & Aging 32:12, pages 983-997.
Crossref
Crossref
Ofir Wolach & Richard M. Stone. 2015. Targeted Therapy in Translational Cancer Research. Targeted Therapy in Translational Cancer Research
89
100
.
Daniel A. Roberts & David P. Steensma. (2015) Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents. Current Hematologic Malignancy Reports 10:3, pages 318-328.
Crossref
Crossref
Michael R. Grunwald & Mark J. Levis. (2015) FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia. Seminars in Hematology 52:3, pages 193-199.
Crossref
Crossref
Walter Fiedler, Sabine Kayser, Maxim Kebenko, Melanie Janning, Jürgen Krauter, Marcus Schittenhelm, Katharina Götze, Daniela Weber, Gudrun Göhring, Veronica Teleanu, Felicitas Thol, Michael Heuser, Konstanze Döhner, Arnold Ganser, Hartmut Döhner & Richard F. Schlenk. (2015)
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating
FLT3
mutations
. British Journal of Haematology 169:5, pages 694-700.
Crossref
Crossref
Monica R. Muppidi, Scott Portwood, Elizabeth A. Griffiths, James E. Thompson, Laurie A. Ford, Craig W. Freyer, Meir Wetzler & Eunice S. Wang. (2015) Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 15, pages S73-S79.
Crossref
Crossref
Ahmad Antar, Mohamed A. Kharfan-Dabaja, Rami Mahfouz & Ali Bazarbachi. (2015) Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation. Clinical Lymphoma Myeloma and Leukemia 15:5, pages 298-302.
Crossref
Crossref
Yi-Bin Chen, Shuli Li, Andrew A. Lane, Christine Connolly, Candice Del Rio, Betsy Valles, Morgan Curtis, Karen Ballen, Corey Cutler, Bimalangshu R. Dey, Areej El-Jawahri, Amir T. Fathi, Vincent T. Ho, Amy Joyce, Steven McAfee, Michelle Rudek, Trivikram Rajkhowa, Sigitas Verselis, Joseph H. Antin, Thomas R. Spitzer, Mark Levis & Robert Soiffer. (2014) Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation 20:12, pages 2042-2048.
Crossref
Crossref
James M. Foran. (2014) Frontline Therapy of AML: Should the Older Patient be Treated Differently?. Current Hematologic Malignancy Reports 9:2, pages 100-108.
Crossref
Crossref
Kendra Sweet & Jeffrey E. Lancet. (2014) Novel Therapeutics in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports 9:2, pages 109-117.
Crossref
Crossref
Jens Hasskarl. 2014. Small Molecules in Oncology. Small Molecules in Oncology
145
164
.
Gary J. Schiller. (2013) High-risk acute myelogenous leukemia: treatment today … and tomorrow. Hematology 2013:1, pages 201-208.
Crossref
Crossref
Denise Wolleschak, Enrico Schalk, Christian Krogel, Tina M Schnoeder, Helga Luehr, Kathleen Jentsch-Ullrich, Thomas Fischer & Florian H Heidel. (2013) Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. Journal of Hematology & Oncology 6:1.
Crossref
Crossref
Michael R. Grunwald & Mark J. Levis. (2013) FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. International Journal of Hematology 97:6, pages 683-694.
Crossref
Crossref